Stay Ahead of the Game With Agilent (A) Q4 Earnings: Wall Street's Insights on Key Metrics

In its upcoming report, Agilent Technologies (A) is predicted by Wall Street analysts to post quarterly earnings of $1.41 per share, reflecting an increase of 2.2% compared to the same period last year. Revenues are forecasted to be $1.67 billion, representing a year-over-year decrease of 0.9%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.With that in mind, let's delve into the average projections of some Agilent metrics that are commonly tracked and projected by analysts on Wall Street.The average prediction of analysts places 'Revenue by End Markets- Pharmaceutical' at $583.30 million. The estimate points to a change of -1.1% from the year-ago quarter.It is projected by analysts that the 'Revenue by End Markets- Academia and Government' will reach $138.29 million. The estimate indicates a year-over-year change of -7.8%.Based on the collective assessment of analysts, 'Revenue by End Markets- Diagnostics and Clinical' should arrive at $243.48 million. The estimate suggests a change of +3.2% year over year.According to the collective judgment of analysts, 'Revenue by End Markets- Chemical and advanced materials' should come in at $385.60 million. The estimate points to a change of +1.2% from the year-ago quarter.Analysts forecast 'Net Revenue- Agilent Crosslab Group' to reach $431.46 million. The estimate indicates a year-over-year change of +6.8%.Analysts expect 'Revenue by End Markets- Environmental and Forensics' to come in at $167.03 million. The estimate points to a change of -4.6% from the year-ago quarter.The collective assessment of analysts points to an estimated 'Net Revenue- Life Sciences and Applied Markets Group' of $819.25 million. The estimate indicates a change of -11.7% from the prior-year quarter.The consensus among analysts is that 'Net Revenue- Diagnostics and Genomics Group' will reach $417.75 million. The estimate indicates a year-over-year change of +17.3%.Analysts predict that the 'Revenue by End Markets- Food' will reach $158.98 million. The estimate points to a change of +1.9% from the year-ago quarter.View all Key Company Metrics for Agilent here>>>Shares of Agilent have experienced a change of -5.8% in the past month compared to the +1% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), A is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilent Technologies, Inc. (A): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks